Physician profile
Charles Montgomery
NPI 1437156197
$5,695.39
in general payments reported to CMS, 2019-2025
57 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $727 · 2021: $651 · 2022: $1,924 · 2023: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $399.43 | 2019-2023 | |
| Amgen INC. | $365.10 | 2019-2023 | Blincyto |
| Astrazeneca Pharmaceuticals LP | $350.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $299.52 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $293.82 | 2020-2023 | Imbruvica |
| Seagen INC. | $287.98 | 2020-2023 | Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $280.26 | 2019-2022 | |
| Pfizer INC. | $278.06 | 2019-2023 | |
| Lilly USA, LLC | $272.54 | 2019-2023 | Jaypirca, Verzenio |
| Incyte Corporation | $181.23 | 2019-2023 | Monjuvi, Jakafi |
| Eisai INC. | $173.70 | 2019-2023 | |
| Janssen Biotech, INC. | $154.94 | 2019-2023 | Darzalex |
| Gilead Sciences, INC. | $152.66 | 2021-2023 | Trodelvy |
| Daiichi Sankyo INC. | $150.84 | 2020-2022 | |
| Genzyme Corporation | $137.79 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.